Skip to content
Screener

Total Equity at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$52.69B+4.3%
Labcorp Holdings logo
Labcorp HoldingsLH
$8.61B+1.6%
IQVIA logo
IQVIAIQV
$6.17B+6.8%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$524.2M-11.0%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$415.56M+89.1%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
-$34.09M-3,860%

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.05B+31.0%
Enterprise value$15.69B+27.0%
P/E32.7×+3.4×
P/S5.8×+0.3×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
(Amounts in thousands, except share amounts)As of / June 30,2026As of / December 31,2025
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock - $0.01 par-value; 250,000,000 shares authorized at June 30, 2026 and December 31, 2025; 27,910,605 and 28,370,780 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively279284
Treasury stock - 69,593 and 69,623 shares at June 30, 2026 and December 31, 2025, respectively(12,151)(12,156)
Additional paid-in capital964,183935,830
Accumulated deficit(511,368)(459,981)
Accumulated other comprehensive loss(7,082)(4,906)
Total shareholders’ equity433,861459,071
Total liabilities and shareholders’ equity$2,057,181$1,975,472

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s total equity?
Medpace Holdings, Inc. (MEDP) reported total equity of $433.86M in Q2 2026.
How has Medpace Holdings, Inc.'s total equity changed year-over-year?
Medpace Holdings, Inc.'s total equity increased by 151.7% year-over-year, from $172.35M to $433.86M.
What is the long-term trend for Medpace Holdings, Inc.'s total equity?
Over 5 years (2020 to 2025), Medpace Holdings, Inc.'s total equity has grown at a -10.6% compound annual growth rate (CAGR), from $805.78M to $459.07M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Medpace Holdings, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude